Biocon retains economic interest in Hulio's global commercialisation - (Business Standard via NewsPoints Desk)

  • Biocon revealed that it has retained an economic interest in Hulio after the therapy was in-licenced by Mylan, as reported Business Standard Tuesday.

  • "Following the successful approval and European launch of Hulio, in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialisation rights have been extended from Europe to global markets," the drugmaker stated.

  • "Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process," a company spokesperson said.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.